Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Purpose
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Local consolidation therapy such as radiation/stereotactic body radiation or surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy and local consolidation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.
Conditions
- Recurrent Non-Small Cell Lung Carcinoma
- Stage IV Non-Small Cell Lung Cancer
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up - Women of childbearing potential and men who are sexually active should be willing and able to use medically acceptable forms of contraception during the trial and for up to 180 days after completion of all treatment to prevent pregnancy or fathering a child. - Pathologically proven diagnosis of NSCLC, with metastases (stage IV disease) present prior to registration; this includes patients newly diagnosed with metastatic disease or those initially diagnosed and treated for stage I-III NSCLC who ultimately develop metastases - Appropriate stage for study entry based on the following diagnostic workup: - History/physical examination within 30 days prior to registration - Imaging proof of limited metastatic disease and response to therapy/stable disease, by at least CT chest through the adrenals or PET/CT within 30 days prior to registration - Zubrod performance status 0, 1, or 2 within 30 days prior to registration - Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of normal (ULN) or ≤ 5 × ULN with metastatic liver disease - Total bilirubin ≤ 1.5 × ULN - Absolute neutrophil count (ANC) ≥ 500 cells/mm^3 - Creatinine clearance ≥ 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal - Platelets ≥ 50,000 cells/mm^3 - Negative serum pregnancy test within one week prior to registration for females of childbearing potential - Patients must have received first-line/induction chemotherapy (4 cycles) and achieved stable disease or a partial response - Prior systemic chemotherapy as part of concurrent treatment approach for previously diagnosed stage III NSCLC, as adjuvant therapy for previously resected NSCLC, or for other previous cancers is permitted - Prior radiotherapy for patients with brain metastases prior to enrollment is acceptable - Patients must have measurable disease at baseline and 3 or fewer discrete, extracranial metastatic disease sites that are technically amenable to SBRT - For de novo stage IV NSCLC patients (patients with metastatic disease at first presentation), primary disease must be treatable with local therapy in the form of SBRT or hypofractionated radiation; if the primary disease is found in the peripheral or central lung parenchyma without nodal disease for instance, SBRT may be employed; if primary disease is more advanced with involvement of the mediastinum (T4 tumor, N1-N3 disease, etc.), these volumes should be technically treatable with hypofractionated radiation - If primary disease in the thoracic cavity was previously treated with local therapy in the form of surgery, any local/regional disease recurrence should be technically treatable with SBRT or hypofractionated radiation after induction systemic therapy - Patients must be registered within 35 days of administration of the last dose of first-line/induction systemic therapy - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry - Patients with brain metastases are eligible if these lesions have been previously treated and the patients have no clinical or radiographic evidence of progression prior to enrollment
Exclusion Criteria
- Clinical or radiologic evidence of untreated and/or progressive brain metastases - Cutaneous metastasis of NSCLC - Metastatic disease invading the esophagus, stomach, intestines, or mesenteric lymph nodes if not a candidate for surgery for these lesions - Prior invasive malignancy (except non-melanomatous skin cancer, low or intermediate risk prostate cancer, or in situ carcinoma of breast, oral cavity, skin, or cervix) unless disease free for a minimum of one year - Metastases located within 3 cm of previously irradiated (< 3Gy per fraction) structures if if not a candidate for surgery for these lesions and if: - Spinal cord previously irradiated to > 40 Gy - Brachial plexus previously irradiated to > 50 Gy - Small intestine, large intestine, or stomach previously irradiated to > 45 Gy - Brainstem previously irradiated to > 50 Gy - Lung previously irradiated with prior V20 Gy > 35% - Patients receiving targeted therapy (non-cytotoxic systemic therapy) for NSCLC in the first-line setting - If a patient has progressed in previous areas of primary disease that received definitive doses of radiation, these patients would require re-irradiation in previous high dose anatomic areas and are not eligible for this study - Patients with malignant pleural effusions that do not resolve after first-line systemic therapy; patients with pleural effusions that have become too small for thoracentesis at the time of registration would be permitted on study, indicating a significant response to first-line chemotherapy - Patients with more than 3 discrete locations of extra-cranial metastatic disease after first-line systemic therapy requiring more than 3 SBRT plans to cover these distinct metastatic disease entities - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration - Patients who are pregnant or nursing - Participation in any investigational drug study (excluding non-oncology and/or symptom management studies) within 4 weeks prior to registration - Known human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol - Patients who received prior non-induction pembrolizumab, patients on chronic steroids or who have active autoimmune disease for which they received systemic treatment in the previous 2 years with corticosteroids, disease modifying agents, or immunosuppressive drugs. Replacement therapy (thyroxine, insulin or physiological corticosteroid replacement for adrenal or pituitary insufficiency) is allowed. Patients with active interstitial lung disease or who have a history of pneumonitis for which they had received glucocorticoids are not eligible - Prior bevacizumab therapy
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Arm 1 (maintenance chemotherapy) |
Patients may receive docetaxel IV over 60 minutes on day 1, erlotinib hydrochloride PO QD, or gemcitabine IV over 30 minutes on days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on day 1 alone or in combination with pembrolizumab IV over 30 minutes. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
|
Experimental Arm 2 (SBRT + maintenance chemotherapy) |
Patients undergo LCT over 2-4 weeks. If LCT cannot be used to treat primary disease sites, patients also undergo IMRT or 3DCRT over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients may possibly undergo surgery. |
|
Recruiting Locations
Birmingham, Alabama 35233
Gilbert, Arizona 85297
Site Public Contact
480-922-4600
Peoria, Arizona 85381
Site Public Contact
623-773-2873
Scottsdale, Arizona 85258
Site Public Contact
480-922-4600
Tucson, Arizona 85704
Site Public Contact
520-694-8900
Tucson, Arizona 85719
Tucson, Arizona 85719
Site Public Contact
800-327-2873
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Duarte, California 91010
La Jolla, California 92093
Orange, California 92868
Site Public Contact
714-734-6220
South Pasadena, California 91030
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80909
Site Public Contact
719-365-2406
Denver, Colorado 80210
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Newark, Delaware 19713
Rehoboth Beach, Delaware 19971
Coral Gables, Florida 33146
Site Public Contact
305-243-2647
Deerfield Beach, Florida 33442
Site Public Contact
305-243-2647
Miami, Florida 33136
Site Public Contact
305-243-2647
Miami, Florida 33176
Site Public Contact
786-596-2000
Miami, Florida 33176
Site Public Contact
305-243-2647
Orlando, Florida 32806
Plantation, Florida 33324
Site Public Contact
305-243-2647
Tampa, Florida 33612
Weston, Florida 33331
Atlanta, Georgia 30303
Site Public Contact
404-489-9164
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Augusta, Georgia 30912
Savannah, Georgia 31405
Nampa, Idaho 83686
Chicago, Illinois 60611
Chicago, Illinois 60612
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Decatur, Illinois 62526
Effingham, Illinois 62401
Galesburg, Illinois 61401
Site Public Contact
309-344-2831
Hines, Illinois 60141
Site Public Contact
708-202-8387
Maywood, Illinois 60153
Site Public Contact
708-226-4357
Park Ridge, Illinois 60068
Site Public Contact
847-384-3621
Peoria, Illinois 61636
Peoria, Illinois 61637
Rockford, Illinois 61114
Springfield, Illinois 62781
Site Public Contact
217-788-3528
Urbana, Illinois 61801
Indianapolis, Indiana 46237
Site Public Contact
317-528-7060
Mooresville, Indiana 46158
Site Public Contact
317-834-3603
Clive, Iowa 50325
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50314
Wichita, Kansas 67214
Edgewood, Kentucky 41017
Lexington, Kentucky 40536
Site Public Contact
859-257-3379
Louisville, Kentucky 40202
Site Public Contact
502-562-3429
Baton Rouge, Louisiana 70805
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Baltimore, Maryland 21201
Site Public Contact
800-888-8823
Columbia, Maryland 21044
Site Public Contact
443-546-1300
Glen Burnie, Maryland 21061
Site Public Contact
410-553-8100
Boston, Massachusetts 02115
Site Public Contact
617-724-5200
Boston, Massachusetts 02118
Site Public Contact
617-638-8265
Bay City, Michigan 48706
Clarkston, Michigan 48346
Clinton Township, Michigan 48038
Detroit, Michigan 48201
Detroit, Michigan 48202
Detroit, Michigan 48236
Farmington Hills, Michigan 48334
Flint, Michigan 48532
Flint, Michigan 48532
Jackson, Michigan 49201
Kalamazoo, Michigan 49007
Lansing, Michigan 48910
Lansing, Michigan 48912
Lansing, Michigan 48912
Lapeer, Michigan 48446
Livonia, Michigan 48154
Mount Clemens, Michigan 48043
Petoskey, Michigan 49770
Pontiac, Michigan 48341
Port Huron, Michigan 48060
Royal Oak, Michigan 48073
Site Public Contact
248-551-7695
Troy, Michigan 48085
Site Public Contact
248-551-7695
Wyoming, Michigan 49519
Bemidji, Minnesota 56601
Minneapolis, Minnesota 55415
Saint Paul, Minnesota 55101
Cape Girardeau, Missouri 63703
Rolla, Missouri 65401
Saint Louis, Missouri 63110
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Great Falls, Montana 59405
Kalispell, Montana 59901
Omaha, Nebraska 68114
Site Public Contact
402-354-5144
Omaha, Nebraska 68124
Reno, Nevada 89502
Dover, New Hampshire 03820
Site Public Contact
603-740-2150
Lebanon, New Hampshire 03756
Basking Ridge, New Jersey 07920
Site Public Contact
212-639-7592
Middletown, New Jersey 07748
Site Public Contact
212-639-7592
Montvale, New Jersey 07645
Site Public Contact
212-639-7592
Bronx, New York 10461
Bronx, New York 10467
Commack, New York 11725
Site Public Contact
212-639-7592
Harrison, New York 10604
Site Public Contact
212-639-7592
New York, New York 10029
New York, New York 10065
Site Public Contact
212-639-7592
Rochester, New York 14642
Site Public Contact
585-275-5830
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Syracuse, New York 13210
Site Public Contact
315-464-5476
Uniondale, New York 11553
Site Public Contact
212-639-7592
Charlotte, North Carolina 28203
Site Public Contact
800-804-9376
Charlotte, North Carolina 28210
Site Public Contact
980-442-2000
Charlotte, North Carolina 28262
Site Public Contact
800-804-9376
Concord, North Carolina 28025
Site Public Contact
800-804-9376
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Monroe, North Carolina 28112
Site Public Contact
980-442-2000
New Bern, North Carolina 28561
Supply, North Carolina 28462
Site Public Contact
910-754-4716
Wilmington, North Carolina 28401
Site Public Contact
910-342-3000
Wilmington, North Carolina 28401
Site Public Contact
910-251-1839
Bismarck, North Dakota 58501
Fargo, North Dakota 58122
Akron, Ohio 44307
Beachwood, Ohio 44122
Chardon, Ohio 44024
Chillicothe, Ohio 45601
Cincinnati, Ohio 45219
Cleveland, Ohio 44106
Cleveland, Ohio 44111
Cleveland, Ohio 44195
Columbus, Ohio 43210
Columbus, Ohio 43219
Mansfield, Ohio 44906
Mayfield Heights, Ohio 44124
Mentor, Ohio 44060
Middleburg Heights, Ohio 44130
Parma, Ohio 44129
Ravenna, Ohio 44266
Sandusky, Ohio 44870
Sandusky, Ohio 44870
Sylvania, Ohio 43560
Site Public Contact
419-824-1842
West Chester, Ohio 45069
Westlake, Ohio 44145
Westlake, Ohio 44145
Wooster, Ohio 44691
Zanesville, Ohio 43701
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73120
Site Public Contact
405-752-3402
Gresham, Oregon 97030
Site Public Contact
503-413-2150
Portland, Oregon 97210
Portland, Oregon 97213
Portland, Oregon 97225
Bryn Mawr, Pennsylvania 19010
Danville, Pennsylvania 17822
Dunmore, Pennsylvania 18512
Site Public Contact
888-808-6762
Harrisburg, Pennsylvania 17109
Lancaster, Pennsylvania 17601
Site Public Contact
717-544-0511
Lancaster, Pennsylvania 17602
Site Public Contact
717-544-5511
Lewisburg, Pennsylvania 17837
Lewistown, Pennsylvania 17044
Paoli, Pennsylvania 19301
Philadelphia, Pennsylvania 19107
Site Public Contact
215-955-6084
Philadelphia, Pennsylvania 19114
Site Public Contact
215-612-5296
Pottsville, Pennsylvania 17901
Sayre, Pennsylvania 18840
Site Public Contact
800-836-0388
West Reading, Pennsylvania 19611
Site Public Contact
610-988-9323
Wilkes-Barre, Pennsylvania 18711
Wynnewood, Pennsylvania 19096
Greenville, South Carolina 29605
Greenville, South Carolina 29607
Greenville, South Carolina 29615
Greer, South Carolina 29650
Greer, South Carolina 29651
Hilton Head Island, South Carolina 29926
Seneca, South Carolina 29672
Spartanburg, South Carolina 29303
Sioux Falls, South Dakota 57117-5134
Memphis, Tennessee 38120
Dallas, Texas 75390
Houston, Texas 77030
Salt Lake City, Utah 84112
Salt Lake City, Utah 84148
Site Public Contact
801-582-1565
Saint Johnsbury, Vermont 05819
Site Public Contact
802-473-4100
Richmond, Virginia 23235
Richmond, Virginia 23298
Vancouver, Washington 98686
Site Public Contact
503-413-2150
Morgantown, West Virginia 26506
Antigo, Wisconsin 54409
Burlington, Wisconsin 53105
Eau Claire, Wisconsin 54701
Fond Du Lac, Wisconsin 54937
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Green Bay, Wisconsin 54311
Kenosha, Wisconsin 53142
La Crosse, Wisconsin 54601
Marinette, Wisconsin 54143
Marshfield, Wisconsin 54449
Menomonee Falls, Wisconsin 53051
Site Public Contact
262-257-5100
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Milwaukee, Wisconsin 53233
Minocqua, Wisconsin 54548
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53406
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54482
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
West Bend, Wisconsin 53095
Site Public Contact
414-805-0505
More Details
- NCT ID
- NCT03137771
- Status
- Recruiting
- Sponsor
- NRG Oncology
Detailed Description
PRIMARY OBJECTIVES: Phase II To evaluate the impact of adding local consolidative therapy (LCT) to maintenance systemic therapy versus maintenance systemic therapy alone on progression-free survival for patients with metastatic non-small cell lung cancer (NSCLC) with no evidence of progression and limited metastatic sites after first-line systemic therapy. Phase III To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on overall survival for patients with metastatic NSCLC with no evidence of progression and limited metastatic sites after first-line systemic therapy. SECONDARY OBJECTIVES: I. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on in-field local failure. II. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on the time to development of new lesions. III. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on toxicity. IV. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on duration of maintenance systemic therapy usage. V. To evaluate the effect of adding LCT to systemic therapy in limited stage IV NSCLC on Quality of Life (QOL) VI. To collect biospecimens and evaluate the correlation between clinical outcomes and circulating tumor DNA (ctDNA). OUTLINE: Patients are randomized into 1 of 2 arms. ARM 1 (CHEMOTHERAPY ALONE): ): Patients may receive docetaxel intravenously (IV) over 60 minutes on Day 1, erlotinib hydrochloride orally (PO) once daily (QD), or gemcitabine IV over 30 minutes on Days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on Day 1 alone or in combination with pembrolizumab IV over 30 minutes. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM 2 (SBRT AND CHEMOTHERAPY): Patients undergo LCT over 2-4 weeks. If LCT cannot be used to treat primary disease sites, patients also undergo intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3DCRT) over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients may possibly undergo surgery. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, then annually thereafter.